Estonian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
multiple sclerosis/albumiin
Link salvestatakse lõikelauale
Leht 1 alates 16 tulemused
Transcranial Magnetic Stimulation (TMS) in Multiple Sclerosis
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
It is based on the hypothesis that the application of transcranial magnetic stimulation (TMS) at 1 Hertz or 5 Hertz in patients with relapsing-remitting multiple sclerosis (RRMS) implies a neuroprotective effect against the progression of the disease, resulting in a clinical improvement (attenuation
Open Trail of γIFN for Friedreich Ataxia
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Friedreich ataxia (FRDA) is a devastating neurodegenerative disease that affects children and young adults. Patients become progressively unable to coordinate movements and walking until severe disability ensues. Most patients develop dilated cardiomyopathy and congestive heart failure. The disease
Incomes of Nutritional Support Modalities in Hemodialysis Patients With Severe Malnutrition
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Our current standard nutrition care is based upon existing recommendations and involves nutrition counselling for optimal dietary intake from food and beverages, food fortification, administration of oral nutrition supplementation (ONS) and/or IDPN in malnourished MHD patients.
Among 712 MHD
Central and Peripheral Nervous System Changes as Markers of Disease Progression in Multiple Sclerosis
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
BACKGROUND Multiple Sclerosis (MS) is an autoimmune, inflammatory demyelinating disease targeting myelinated axons in the Central Nervous System (CNS). It is the most common nontraumatic cause of disability in young people. Most MS patients are diagnosed between the ages of 20 and 40 years. Denmark
Vitamin D Supplementation and Sunlight Exposure in Brazilian Women Living in Opposite Latitudes (The D-SOL Study)
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
During this study the subjects were asked to visit the Clinical Investigation Unit, FHMS, University of Surrey in the UK or the Research Clinic, Faculty of Nutrition, Federal University of Goiás in Brazil, on two occasions, at the beginning of the study for baseline measurements and at the
Non-interventional Study to Assess Adherence to Treatment for Patients With Relapsing Multiple Sclerosis
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Single Dose Administration of Alpha-1 Anti-Trypsin for the Amelioration of Organ Injury in Patients Undergoing Cardiac Surgery
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
3 Background The use of cardiopulmonary bypass (CPB) during cardiac surgery elicits generalized non-specific systemic inflammatory response syndrome (SIRS) and subsequent activation of the cytokine, complement, and coagulation-fibrinolytic cascades (1). In approximately 11% of the patients SIRS may
Umbilical Cord Mesenchymal Stem Cells for Patients With Primary Biliary Cirrhosis
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Primary biliary cirrhosis (PBC) is a slowly progressive cholestatic disease associated with the development of cirrhosis and liver failure that may justify liver transplantation. Ursodeoxycholic acid (UDCA) is currently the only drug approved specifically for the treatment of PBC. However, one out
The Effects of Interferon Beta Combined With Vitamin D on Relapsing Remitting Multiple Sclerosis Patients
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Detailed Description of Study Evaluations
Adherence to treatment evaluation:
Patients will be asked to bring the empty packages of the IFN beta and Vitamin D that were used during the study.
Flu like symptoms and Injection site reactions evaluation:
Data regarding FLS and ISRs will be collected by
Functional and Physiological Responses to Lokomat Therapy (Pilot Study)
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Description of the Clinical Lokomat Therapy program:
This is a 12-week program with 3 to 5 sessions per week. Each session includes: 15-20 minutes of patient set-up (set-up time becomes about 5 to 10 minutes after a few sessions), 5-10 minutes of warm-up, 20-40 minutes of Lokomat therapy, 5-10
Long-term Follow-Up of Patients Who Participated in Study 27025 (REFLEX)
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
The objective of the study is to investigate whether RNF treatment initiated after the first clinical event versus delayed treatment results in the prolongation of time to Clinically Definite Multiple Sclerosis (CDMS) conversion up to Month 36 and up to Month 60 since randomization in Study 27025
Botox-A Injection to Improve Bladder Function in Early Spinal Cord Injury (#H-20344)
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Approximately 10,000 spinal cord injuries (SCI) occur each year, most of which occur in males (80%). Many of these patients develop neurogenic bladder dysfunction (NGB) characterized by overactivity of the detrusor muscle, termed detrusor overactivity (DO) or detrusor hyperreflexia (DH). They can
REbif FLEXible Dosing in Early Multiple Sclerosis (MS)
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Immune Globulin Intravenous (IGIV) To Treat Relapsing, Remitting Multiple Sclerosis
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
This trial is designed as a multi-national, randomized, double-blind, placebo-controlled prospective trial with three parallel groups.
One hundred twenty (120) patients, 40 per treatment arm, with relapsing-remitting (RR) multiple sclerosis will be enrolled in this trial. Eligible patients must have
Rebif New Formulation (RNF) in Relapsing Forms of Multiple Sclerosis
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
As has been seen with other recombinant protein molecules, the use of injectable recombinant proteins may result in the development of neutralising antibodies (NAbs). Antibodies are considered neutralising by their ability to inhibit the biological effect of interferon in a bioassay system. EMD
Kõige täiuslikum ravimtaimede andmebaas, mida toetab teadus
- Töötab 55 keeles
- Taimsed ravimid, mida toetab teadus
- Maitsetaimede äratundmine pildi järgi
- Interaktiivne GPS-kaart - märgistage ürdid asukohas (varsti)
- Lugege oma otsinguga seotud teaduspublikatsioone
- Otsige ravimtaimi nende mõju järgi
- Korraldage oma huvisid ja hoidke end kursis uudisteuuringute, kliiniliste uuringute ja patentidega
Sisestage sümptom või haigus ja lugege ravimtaimede kohta, mis võivad aidata, tippige ürdi ja vaadake haigusi ja sümptomeid, mille vastu seda kasutatakse.
* Kogu teave põhineb avaldatud teaduslikel uuringutel
